The Human Cancer Models Initiative aims to create about 1,000 cancer cell lines that scientists can use to study tumor progression, drug resistance, and more.
TheSTARPlatform includes tools for analyzing genomic data from raw sequence through to variants calls as well as for compressing and storing data.
Consortium researchers will use the STARPlatform to manage whole exome and genome sequence from patients with three diffuse glioma subtypes.
The Food Allergy Science Initiative seeks to supply the basic scientific research needed to spur future development of diagnostics and therapeutics.
The researchers will use Sapientia to analyze samples from 1,000 fetuses as part of efforts to develop an exome-based assay for non-invasive prenatal testing.
MetaSUB researchers will sample high-traffic areas across subway systems, buses, and parks in cities such as New York, San, Francisco, Buenos Aires, Sydney, and London.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The portal offers access to genotype, phenotype, and clinical data related to type 2 diabetes as well as computational tools for querying the information.
Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.
The White House Office of Science and Technology Policy is collaborating with federal agencies and private companies to study microbiomes in different ecosystems.
Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.
An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.
Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.
In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.